NCT05457998

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Butler Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This research study aims to examine biomarkers of Alzheimer's disease as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Memory and Aging Program at Butler Hospital. The study will enroll up to 200 cognitively healthy subjects aged 50 to 80 years with ongoing recruitment and enrollment for 2 years, and subject participation lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure. Two PET imaging sub-studies will also be optional.

Conditions

• Alzheimer Disease
• Mild Cognitive Impairment
• Dementia

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Flutemetamol F18 Injection	PET imaging of Abeta amyloid
DIAGNOSTIC_TEST	[18F]-RO6958948 Injection	PET imaging of Tau aggregates
DIAGNOSTIC_TEST	[18F]-MK-6240 Injection	PET imaging of Tau aggregates

Timeline

• Start date: 2023-06-14
• Primary completion: 2028-06-01
• Completion: 2028-06-01
• First posted: 2022-07-14
• Last updated: 2024-12-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study